Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - Natural history of the disease and the effect of vitamin e treatment. Meta-analysis of the medical literature

European Journal of Internal Medicine

Volumn 23, Issue 7, 2012, Pages 628-632

  Vardi, Moshe ^a,b   Blum, Shany ^c   Levy, Andrew P ^c  

^a CARMEL MEDICAL CENTER   (Israel)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cardiovascular complications; Diabetes mellitus; Haptoglobin; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; HAPTOGLOBIN; PLACEBO;

ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC PATIENT; GENETIC RISK; GENOTYPE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; MEDICAL HISTORY; META ANALYSIS; STROKE; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION;

ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; GENOTYPE; HAPTOGLOBINS; HUMANS; MYOCARDIAL INFARCTION; PHARMACOGENETICS; RISK FACTORS; STROKE; VITAMIN E;

EID: 84865680790     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.04.009     Document Type: Article

References (26)

1. K.M.V. Narayan, J.P. Boyle, T.J. Thompson, S.W. Sorensen, and D.F. Williamson Lifetime risk for diabetes mellitus in the United States JAMA 290 2003 1884 1890
2. J.P. Boyle, A.A. Honeycutt, K.M.V. Narayan, T.J. Hoerger, L.S. Geiss, and H. Chen Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24 2001 1936 1940
3. H. King, R.E. Aubert, and W.H. Herman Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
4. K.M.V. Narayan, E.W. Gregg, A. Fagot-Campagna, M.M. Engelgau, and F. Vinicor Diabetes - a common, growing, serious, costly, and potentially preventable public health problem Diabetes Res Clin Pract 50 2000 S77 S84
5. P.R. Moreno, and V. Fuster New aspects in the pathogenesis of diabetic atherothrombosis J Am Coll Cardiol 44 2004 2293 2300
6. American Diabetes Association Economic costs of diabetes in the U.S. in 2007 Diabetes Care 31 2008 596 615
7. The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
8. The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
9. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
10. The ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010
11. B.H. Bowman, and A. Kurosky Haptoglobin. The evolutionary product of duplication, unequal crossing over, and point mutation Adv Hum Genet 12 1982 189 261
12. M. Melamed-Frank, O. Lache, B.I. Enav, T. Szafranek, N.S. Levy, and R.M. Ricklis Structure-function analysis of the antioxidant properties of haptoglobin Blood 98 2001 3693 3698
13. T. Costacou, R.E. Ferrell, and T.J. Orchard Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes Diabetes 57 2008 1702 1706
14. A.P. Levy, I. Hochberg, K. Jablonski, H.E. Resnick, E.T. Lee, and L. Best Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study J Am Coll Cardiol 40 2002 1984 1990
15. U. Milman, S. Blum, C. Shapira, D. Aronson, R. Miller-Lotan, and Anbinder Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial Arterioscler Thromb Vasc Biol 28 2008 341 347
16. A. Roguin, W. Koch, A. Kastrati, D. Aronson, A. Schomig, and A.P. Levy Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes Diabetes Care 26 2003 2628 2631
17. M. Suleiman, D. Aronson, R. Asleh, M.R. Kapeliovich, A. Roguin, and S.R. Meisel Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction Diabetes 54 2005 2802 2806
18. S. Blum, M. Vardi, N.S. Levy, R. Miller-Lotan, and A.P. Levy The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes Atherosclerosis 211 2010 25 27
19. K.F. Schulz, I. Chalmers, R.J. Hayes, and D.G. Altman Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 237 1995 408 412
20. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, and D.J. Gavaghan Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1996 1 12
21. Z. Burbea, F. Nakhoul, R. Zoabi, I. Hochberg, N.S. Levy, and S. Benchetrit Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients Ann Clin Biochem 41 2004 469 473
22. A.P. Levy, H.C. Gerstein, R. Miller-Lotan, R. Ratner, M. McQueen, and E. Lonn The effect of vitamin e supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes Diabetes Care 27 2004 2767
23. S. Yusuf, G. Dagenais, J. Pogue, J. Bosch, and P. Sleight Vitamin E supplementation and cardiovascular events in high risk patients N Engl J Med 342 2000 154 160
24. I.M. Lee, N.R. Cook, J.M. Gaziano, D. Gordon, P.M. Ridker, and J.E. Manson Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial JAMA 294 2005 56 65
25. J.L. Witztum The oxidation hypothesis of atherosclerosis Lancet 344 1994 793 795
26. V.V. Bamm, V.A. Tsemakhovich, M. Shaklai, and N. Shaklai Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL Biochemistry 43 2004 3899 3906